Published: 2020-11-27

Radical radiotherapy in epidermoid cancer in the orbitary region: ideal scheme of hypo-fractionation in times of COVID-19: a case report

Ruben A. Lara Romero, Karilu Muñoz Jimenez, Amelia E-Sarricolea Puch, Fernando H. Castillo Lopez


There are adverse events in the patient's environment that impact on therapeutic decisions and become a medical challenge, as is currently the management of cancer patients with radiotherapy, particularly the elderly in times of a COVID-19 pandemic, due the high risk of infection and fatal complications from non-cancer causes. Here we present the case of an 84-year-old woman with voluminous squamous cell cancer in the left orbital region, which caused intense pain, stench, and persistent bleeding. And due to persistence and time, it impacted with deterioration in the patient’s quality of life. In the end, of hypo fractionated radiotherapy management as the only modality, it evolves with a complete clinical response and total palliation of initial symptoms. The reasons for the decision to manage radiotherapy and the excellent clinical results that reinforce the idea of personalized medicine and the importance of evaluating the biopsychosocial environment of the cancer patient will be discussed.


SARS, Corona virus, Radiotherapy, Cancer, Epidermoid

Full Text:



Registro nacional de coronavirus en México. Available at Accessed September 28 2020.

Grewal AS, Jones J, Lin A. Palliative Radiation Therapy for Head and Neck Cancers. Int J Rad Oncol, biol, physics. 2019;105(2):254-66.

Porceddu SV, Rosser B, Burmeister BH, Jones M, Hickey B, Baumann K et al. Hypofractionated radiotherapy for the palliation of advanced head and neck cancer in patients unsuitable for curative treatment, Hypo Trial. Radiotherapy and oncology. J Eur Society Therap Radiol Oncol. 2007;85(3):456-62.

Nguyen NT, Doerwald-Munoz L, Zhang H, Kim DH, Sagar S, Wright JR et al Hypofractionated palliative radiotherapy: an effective treatment for advanced head and neck cancers. Bri J radiol. 2015;88(1049):20140646.

Fortin B, Khaouam N, Filion E, Nguyen-Tan PF, Bujold A, Lambert L. Palliative Radiation Therapy for Advanced Head and Neck Carcinomas: A Phase 2 Study. Int J Radiat Oncol Biol Phys. 2016;95(2):647-53.

Das S, Thomas S, Pal SK, Isiah R, John S. Hypofractionated Palliative Radiotherapy in Locally Advanced Inoperable Head and Neck Cancer: CMC Vellore Experience. Indian journal of palliative care. 2013;19(2):93-8.

Kancherla KN, Oksuz DC, Prestwich RJ, Fosker C, Dyker KE, Coyle CC et al. The role of split-course hypofractionated palliative radiotherapy in head and neck cancer. Clin oncol. 2011;23(2):141-8.

Stern RS. Prevalence of a history of skin cancer in 2007: results of an incidence-based model. Arch Dermatol. 2010;146:279-82.

Rubio-Casadevall J, Hernandez-Pujol AM, Ferreira-Santos MC, Morey-Esteve G, Morey-Esteve G, Morey-Esteve G et al. Trends in incidence and survival analysis in nonmelanoma skin cancer from 1994 to 2012 in Girona, Spain: a population-based study. Cancer Epidemiol. 2016;45:6-10.

Kil WJ, Camphausen K. Cyclical hypofractionated radiotherapy also known as "QUAD Shot" alone using intensity-modulated radiotherapy for squamous cell carcinoma of the parotid gland in an 85-year-old patient with multiple comorbidities. Head Neck. 2017;39:E55-60.

Chen AM, Vaughan A, Narayan S, Vijayakumar S. Palliative radiation therapy for head and neck cancer: toward an optimal fractionation scheme. Head Neck. 2008;30:1586-91.